A Phase I trial of of AUR-101, a ROR gamma inverse agonist for autoimmune disorders like psoriasis
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2018
At a glance
- Drugs AUR 101 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; First in man
- Acronyms INDUS
- 11 Jul 2018 According to an Aurigene media release, data from this study is expected by December, 2018.
- 11 Jul 2018 According to Aurigene media release, company has commenced dosing in this trial.
- 11 Jul 2018 According to Aurigene media release,Status changed from planning to recruiting.